NCT06349837 2025-12-17
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
Sichuan University
Phase 1 Recruiting
Sichuan University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School